PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “BREAST NEOPLASMS”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 55 records · Page 3Linked to original sources
PubMed1976

[Role of thermography in the diagnosis of breast neoplasms].

319 cases of breast pathology of doubtful clinical diagnosis were studied by means of thermography and mammography, with histological verification: 214 proved to be malignant tumours and 105 benign. The role of thermography is discussed on the basis of these results; it would appear to be restricted to diagnostic aid status associated with other procedures, particularly clinical examination and mammography.

Adenocarcinoma↗
PubMed1989

[Diagnostic and therapeutic concepts in breast neoplasms].

Therapeutic decisions in breast cancer are no longer as simple and straightforward as they were. Radical masectomy has long ceased to be a routine application to every patient. A number of patients are now candidates for conservative surgery combined with irradiation. Patients who still require total mastectomy with axillary clearance may wish to undergo immediate or delayed breast reconstruction. In our department most patients with breast tumors are first seen in the outpatient clinic, where diagnostic work-up is completed and the therapeutic concept is discussed. If necessary, consultation with the radiotherapist and the plastic surgeon is available. Our diagnostic and therapeutic concepts are summarized in Fig. 1 and Table 1.

Breast↗
PubMed1977

[Medical therapy of the metastasizing breast neoplasm].

For the metastasized breast cancer the indication for the ablative and additive hormonal treatment and/or for the combination chemotherapy is clearly outlined. The hormonal treatment should always be used first because of its good compatibility unless the prognostic assumptions are unfavorable, such as short intervals between primary treatment and recidivation or appearance of metastases and a visceral metastatic formation. In these cases a combination chemotherapy or a combined hormonal/cytostatic treatment should be applied. Various combination chemotherapy schedules are discussed and compared in regard to effectiveness, compatibility, side effects and dispensation. A final judgement for an additional immunological therapy and adjuvant chemotherapy of the pretreated breast cancer cannot be given.

Adrenalectomy↗
PubMedDate not supplied

[Immunomorphological characteristics of primary and recurrent breast neoplasms].

Primary and recurring breast carcinomas do not differ in the expression of proliferating cell nuclear antigen (PCNA), C-erb-2 oncoprotein, carcinoembryonic antigen and trophoblastic antigen. The content of PCNA and C-erb-2 oncoprotein is twice as high in tumors with an unfavorable prognosis and the frequency of combination of these markers is much higher comparing to tumors with a good prognosis.

Biomarkers, Tumor↗
PubMed1995

Pattern of gene alterations in intraductal breast neoplasms associated with histological type and grade.

To reveal any association between the histological type and grade of intraductal breast neoplasms and the manner of accumulation of gene alterations, eight types of gene alterations, i.e., loss of heterozygosity (LOH) on chromosomal arms 16p, 16q, 17p, 17q, and 18q, amplification of the c-erbB-2 and hst-1/int-2 genes, and mutation of the p53 gene, were examined by Southern blot analysis or single-strand conformation polymorphism analysis in a total of 60 cases of intraductal breast cancer and 18 nonmalignant proliferative lesions. Among the histological types and three histological grade groups of intraductal carcinomas, the gene alterations which occurred most frequently were LOH on 16q alone in non-comedo type and Grade 1, alterations of c-erbB-2, 17p, and 16q in comedo type and Grade 2, and alterations of 17q and p53 as well as those of 16q, 17p, and c-erbB-2 in Grade 3. LOH on 16q and 18q was frequent in intraductal carcinoma of the intracystic papillary type, whereas LOH on 18q alone was detected in 27% of papillomas. Among intraductal carcinomas, the mean number of gene alterations was largest in comedo type and Grade 3, whereas it was smallest in non-comedo type and Grade 1. It was possible that LOH on 18q and 16q was involved frequently in papillary tumori-genesis and acquisition of malignant phenotype, respectively, whereas most of the other gene alterations were involved in acquisition of aggressive biological properties by intraductal carcinoma cells. It was also possible that the phenotype of breast neoplasms was determined by the combination of gene alterations at a relatively early developmental stage.

Breast Neoplasms↗
PubMed1979

[CEA and breast neoplasms: application of a personal method for determination of CEA in the clinical study of 242 patients (author's transl)].

The authors report their experience of the clinical application of monitoring serum CEA levels in breast tumours, obtained by a new direct method of determination. A total of 242 patients were studied: 124 with benign tumours, 75 with primary carcinoma in various stages; and 43 who had previously undergone to surgery for breast carcinoma. The analysis of pre-surgical specimens demonstrate consistently normal values for the benign tumors, whereas patients with malignant tumours had positive values in 40 p. 100 of cases. Significant differences in values were seen between benign tumours and Stage II malignant tumours, and between Stage II and Stage III tumours, whereas there was no significant difference between benign forms and Stage I, and between Stage III and Stage IV. In patients with metastases, followed up after surgery, the CEA was positive in 94 p. 100 of the cases. In the opinion of the authors, CEA levels do not seem to be useful for the early diagnosis of malignant breast tumours but are important, harmless and inexpensive, in the follow-up of patients who have undergone surgery for breast neoplasms.

Adult↗
PubMed1999

Ultrasonography of malignant breast neoplasms. Analysis of carcinomas missed as tumor.

PURPOSE: To analyze the malignant breast neoplasms missed as tumor on ultrasonography (US). MATERIAL AND METHODS: A total of 355 malignant tumors were confirmed at histology among 2,985 consecutive patients who underwent breast US. There were no prospectively recorded mammographic findings in 28 of the 355 tumors. The remaining 327 tumors included 16 ductal carcinomas in situ (DCIS) and 66 invasive carcinomas with suspicious microcalcifications on mammography. Excluding these 82 tumors because US would not have been indicated using strict criteria, a subpopulation of 245 noncalcified invasive malignant tumors remained for analysis. The neoplasms missed as tumor on US were analyzed for the whole tumor group (n=355) and the subpopulation (n=245). RESULTS: 42 (11.8%) of the 355 malignant neoplasms were missed as tumor on US, including 6 (2.5%) of the 243 palpable and 36 (32.1%) of the 1 12 nonpalpable malignancies. Most of the missed tumors were DCIS and microinvasive ductal carcinomas dominated by DCIS. In the subpopulation, 14 (5.7%) of the 245 malignancies were missed as tumor on US, including 4 (2.2%) of the 180 palpable and 10 (15.4%) of the 65 nonpalpable lesions. Of the 245 malignancies, 6 (2.4%) had a normal US finding, including 2 palpable retropapillary tumors and 4 incidental findings at histology. CONCLUSION: Using strict criteria for performing US as an adjunct to mammography, by far the most malignant breast neoplasms are diagnosed as a tumor on US.

Adolescent↗
PubMed1986

Neoplasms in skin and subcutis over the breast, simulating breast neoplasms: case reports and literature review.

Twenty cases of neoplasms in skin and subcutaneous tissue over the breast were reviewed. There were 17 women, from 15 to 70 years of age, and three men, from 25 to 66 years of age. Among the benign skin neoplasms, superficial leiomyoma, granular cell tumor, and eccrine acrospiroma were misdiagnosed clinically as primary breast carcinoma. Among the malignant neoplasms in subcutaneous tissue, there were three metastatic malignant melanomas, one metastatic epidermoid bronchogenic carcinoma, and two malignant lymphomas. It is interesting that four of these six patients had no prior history of malignant lesion, the subcutaneous nodule presenting as the first manifestation of an occult primary. It is concluded that histological diagnosis of such tumors may lead to avoidance of unnecessary radical surgery.

Adenoma, Sweat Gland↗
PubMed1987

Circulating secretory component in breast neoplasms.

The serum concentrations of IgAp and IgMr associated secretory component (SIgA and SIgM) of 98 patients with neoplasms of the breast were measured. Of the 56 patients with carcinomas, 11 had increased concentrations of circulating SIgM, which was almost twice as sensitive as SIgA as a marker for carcinoma. Concentrations of circulating SIgA and SIgM were independent of expression of secretory component, IgA, and carcinoembryonic antigen (CEA); histological tumour grade; and tumour cell DNA ploidy, whereas a weak correlation between SIgA and SIgM and circulating CEA was seen. The three patients who had liver metastases indicated had particularly high concentrations of circulating SIgA and SIgM, whereas no difference was generally seen between patients with malignancy and those with benign tumours.

Adult↗
PubMed1984

Influence of interferon on C19-steroids in urine of malignant skin melanoma and malignant breast neoplasm patients.

The paper evaluates the effect of human leukocyte interferon (HLI) in patients with malignant skin melanoma and malignant neoplasm of the breast. HLI was administered intramuscularly in a daily dose of 2 X 10(5) IU 7 days at 8-week intervals over a period of 12 months. The chosen patients were in the surgical stage of the disease, i.e. they had undergone surgical operation on the primary tumor or on the regional lymph nodes T1-3, N0-1, M0. During the HLI treatment the values of C19-steroid metabolites and particularly of Dehydroepiandrosterone (DHA) were established and the following conclusions have been drawn: the application of HLI in a dose of 2 X 10(5) by the described method has an impact on the change of C19 steroid metabolism in terms of normalization.

Adult↗
PubMed1996

Silencing of the mammary-derived growth inhibitor (MDGI) gene in breast neoplasms is associated with epigenetic changes.

Recently, we reported that breast cancer cell lines fail to express the gene encoding the fatty acid binding protein mammary derived growth inhibitor (MDGI) and that transfection with an MDGI expression vector results in suppression of the malignant phenotype, suggesting that MDGI is a tumor suppressor gene. We also demonstrated that homozygous deletion and point mutation are not common mechanisms for silencing of the MDGI gene in human breast neoplasms. We now report that hypermethylation of HpaII and HhaI sites upstream of the first exon of the MDGI gene, and a SacII site in the first intron, occurs frequently in human breast cancer cell lines. This distinct methylation pattern is associated with loss of transcription and is reversible by treatment with 5-aza-deoxycytidine. Primary breast tumors also exhibited methylation of the SacII site (19 of 35, 54.3%) and the HpaII and HhaI sites (21 of 35, 66%). Hypermethylation of these sites was correlated with the absence of MDGI mRNA in these tumors. Our results suggest that epimutation of the MDGI gene leads to silencing, which, in turn, may initiate or contribute to progression of breast cancer.

Azacitidine↗